SK Biopharmaceuticals has licensed its diazepam nasal spray for an undisclosed amount to Seoul, Korea-based Hanmi Pharmaceuticals, giving Hanmi marketing rights for China and Korea. Hanmi expects to launch the nasal spray in Korea in 2013 and in China in 2015. In the US, SKBP licensed the product to Neuronex, which was acquired by Accorda earlier this year.
SKBP CEO Christopher Gallen commented, “SKBP has excellent capabilities to develop new drugs and Drug Delivery System required by the market. We expect the deal signing with Hanmi Pharmaceutical Co, which have excellent marketing platform in China and Korea, will give both parties quite good synergistic effect.”
Read the SKBP press release.
